Rising Tide Foundation for Clinical Cancer Research and The Leukemia & Lymphoma Society Collaborate to Tackle Blood Cancers 

July 3, 2024

Rising Tide for Clinical Cancer Research (RTFCCR) and The Leukemia & Lymphoma Society (LLS) value the impact of the research from investigator-initiated trials (IITs) as they play an important role in addressing unmet medical needs in blood cancers and related pre-malignant conditions by working on ways to improve patient outcomes. To support this important aspect of research, RTFCCR and LLS have established a partnership under the LLS Academic Clinical Trials Program.

LLS/RTFCCR ACT Program Scope 

The program aims to develop novel approaches to the treatment of hematological malignancies and related pre-malignant conditions. Within this collaboration, researchers will have the opportunity to conduct patient-centered phase 1 or 2 trials involving new experimental treatments, whether they are biological or chemical agents, either individually or in combination. Repurposing of existing agents into novel diseases is also considered. These awards will support up to three clinical trials, allotting up to $1M USD over a period of up to three years. 

The program will be conducted under two funding cycles:  

  1. The first cycle will open in the Summer of 2024   
  2. The second cycle will open in the Winter of 2025.  

Trials that are ready to launch or close to being ready to launch will be more competitive. Hence, if a trial proposal needs more development, it may be advantageous to postpone the application until the winter cycle. 

For the first cycle, the deadline for Letter of Intent (LOI) submission is August 1, 2024, at 3 PM ET via the LLS Research Portal (https://lls.fluxx.io). The applicant should carefully craft the information requested in the LOI as this information is automatically populated into the full application.  Applicants will be notified via an automated email whether they are invited to submit a full application, or whether their LOI is declined. If the applicant is invited to submit a full application, immediate access to the full application phase is enabled in the LLS Research Portal.  

The deadline to submit all full applications is September 16, 2024, at 3 PM ET.  

Full Applications will only be accepted via the LLS Research Portal (https://lls.fluxx.io). 

About The Leukemia & Lymphoma Society  

The Leukemia & Lymphoma Society® (LLS) is the global leader in the fight against blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease, and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.  Founded in 1949 and headquartered in Rye Brook, NY, LLS has regions throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.   

For additional information, visit lls.org/lls-newsnetwork. Follow us on Facebook, X, and Instagram. 

About Rising Tide Foundation for Clinical Cancer Research

Rising Tide Foundation for Clinical Cancer Research is a charitable, non-profit organization established in 2010 and located in Schaffhausen, Switzerland. RTFCCR’s primary consideration in granting support is given to truly innovative, unique, patient-centered clinical research. With patients at the core of the mission, the foundation strives to support clinical trials resulting in the creation of less toxic therapeutic approaches, better disease burden management, earlier cancer detection, and innovative intervention strategies that will lead to increased survival and quality of life. 



Scroll to Top